Potentiated immune responses after administration of aclacinomycin.
After the intraperitoneal injection of aclacinomycin into mice, a variety of immune responses were increased. The total plaque-forming spleen cell response to SRBC was higher in treated animals than in controls, in spite of an apparent cytotoxic effects on B cells. The aclacinomycin-sensitive cell is apparently a long-lived cell, surviving adult thymectomy. Delayed-type hypersensitivity reactions were also augmented in treated animals, particularly those bearing tumors. In adjuvant-treated mice, the injection of aclacinomycin augments the immune response still further. Such observations should be taken into account in the establishment of clinical protocols associating immunotherapy and chemotherapy.
D015250:Aclarubicin / Q000031:analogs & derivatives*; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D000921:Antibody-Producing Cells / Q000276:immunology; D001500:BCG Vaccine / Q000494:pharmacology; D005354:Fibrosarcoma / Q000188:drug therapy / Q000276:immunology; D006462:Hemolytic Plaque Technique; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular / Q000187:drug effects; D007274:Injections, Intraperitoneal; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009279:Naphthacenes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D012756:Sheep
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D009279:Naphthacenes; C011157:aclacinomycins; D015250:Aclarubicin